Gyre Therapeutics, Inc. revenue
Gyre Therapeutics, Inc.'s revenue was $117m in fiscal 2025, up 10.2% on the year before. Since fiscal 2009 ($25.1m) it has grown at a compound 12.6% a year. Over the last twelve months it was $119m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2017Dec 2017 | 2018Dec 2018 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25 | 86 | 98 | 58 | 4 | 0 | 1 | 0 | 21 | 7 | 102 | 113 | 106 | 117 | 119 |
| Growth on the year before | — | +242.0% | +13.9% | −40.7% | −93.7% | −92.4% | +270.2% | −99.4% | +>999% | −65.0% | +>999% | +10.9% | −6.8% | +10.2% | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | 97 | 109 | 102 | 111 | 113 |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Gyre Therapeutics, Inc. | $119m | 13.5% | 153.4% |
| Niagen Bioscience, Inc. | $129m | 11.0% | 16.8% |
| Eton Pharmaceuticals, Inc. | $106m | 81.5% | 53.8% |
| Zevra Therapeutics, Inc. | $136m | 119.4% | 101.9% |
| Natural Alternatives International Inc | $143m | 9.7% | -2.6% |
| Heron Therapeutics, Inc. | $151m | 1.0% | 8.6% |
Compare with peers
- Niagen Bioscience, Inc. revenue
- Eton Pharmaceuticals, Inc. revenue
- Zevra Therapeutics, Inc. revenue
- Natural Alternatives International Inc revenue
- Heron Therapeutics, Inc. revenue
Head to head: GYRE vs NAGEETON vs GYREGYRE vs ZVRA
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies